MANAGEMENT
 |
Nassim Usman, Ph.D., Chief Executive Officer | |
Dr. Usman is currently CEO and a member of the Board of Directors at Catalyst Biosciences. Dr. Usman joined Catalyst from Morgenthaler Ventures, where he is a Venture Partner. Prior to joining Morgenthaler in 2005, he was Senior Vice President and Chief Operating Officer at Sirna Therapeutics Inc. (Nasdaq:RNAI – acquired by Merck NYSE:MRK) from 2004 to 2005 and held various R&D positions at both Sirna and Ribozyme Pharmaceuticals (Nasdaq:RZYM), including VP of R&D and Chief Scientific Officer, from 1992 to 2004. During his industrial career Dr. Usman has entered several drugs into clinical development, completed multiple licensing deals with pharmaceutical and biotechnology companies and raised capital in both private and public financings. Prior to moving into the biotechnology industry in 1992, Dr. Usman was an NIH Fogarty and NSERC Postdoctoral Fellow and Scientist in the Departments of Biology and Chemistry at the Massachusetts Institute of Technology from 1987 to 1992. He has authored more than 70 scientific articles and 130 patents and applications. Dr. Usman serves on the Boards of Mosaic Biosciences, Principia Biopharma and Osprey Pharmaceuticals, is a past director of Archemix Corporation (Cambridge, MA) and atugen AG (now Silence Therapeutics, LSE/AIM:SLN) and served on the SABs of RXi Pharmaceuticals and Noxxon Pharma AG. He received his B.Sc. (Honours) and Ph.D. in Organic Chemistry from McGill University. In his doctoral dissertation he developed a method for the solid-phase synthesis of RNA that is widely used in science and in a marketed RNA product (Macugen™). |
||
 |
Edwin L. Madison, Ph.D., Chief Scientific Officer | |
| Dr. Madison received a Ph.D. in biochemistry from University
of Texas - Southwestern Medical Center (UTSWC) in 1990. Following
graduation, Dr. Madison accepted a faculty position at UTSWC
with joint appointments in the Departments of Biochemistry and
Internal Medicine. Dr. Madison then moved to The Scripps Research
Institute as an Associate Professor of Vascular Biology. Prior
to moving to Catalyst Biosciences, Dr. Madison was Vice President
of Biological Research at Dendreon San Diego and Dendreon Corporation,
Professor of Vascular Biology at the Torrey Pines Institute for
Molecular Studies, and Adjunct Professor of Vascular Biology
at The Scripps Research Institute. Dr. Madison has achieved an
international reputation in the fields of serine protease and
serpin basic research, and he is one of the lead inventors of
a currently marketed protease therapeutic agent. |
||
 |
Mike Smith, Chief Financial & Business Advisor | |
Mr. Smith has served as Catalyst Biosciences’ Chief Financial & Business Advisor since June 2012. He brings over 15 years experience in the biopharmaceutical industry in executive and management roles in Corporate Development, Strategy, Finance, Commercial and Project Management functions for companies ranging in size from 5,000 to 10 employees. Mr. Smith was most recently at iPierian as Vice President of Business Development. Prior to that, he served as CFO and Head of Business Development for Memory Pharmaceuticals (Nasdaq: MEMY), which was acquired by Roche in 2009, where he was responsible for overseeing all business development, finance, strategic planning, intellectual property and eventually site operation activities. Prior to Memory, Mr. Smith was Vice President of Business Development at QLT, Inc. (Nasdaq: QLTI). Mr. Smith entered the industry with Chiron (Nasdaq: CHIR) which was acquired by Novartis in 2006. Throughout his career, Mr. Smith has managed and led numerous hundred+ million dollar company acquisitions, product licensing transactions and strategic partnerships and financings. Mr. Smith holds a B.S. from the University of Virginia, as well as an MBA from the University of California, Berkeley. |
||
